Sieger Healthcare Acquisition registered to raise $75 million through an offerign of 7.5 million units, each consisting of one Class A ordinary share and one-third of a warrant.
The new SPAC expects to draw on management’s experience to identify and acquire a target in the biotechnology and pharmaceutical sectors.
Chairman and CEO Xuan (Frank) Sun is an independent director of Bombax Healthcare Acquisition. He previously served as executive director and vice chairman of Shenzhen Hepalink Pharmaceutical Group, a Hong Kong- and Shenzhen-listed global pharmaceutical company.
Piper Sandler is managing the offering. The underwriters may opt to purchase up to an additional 1.125 million units.
Sieger has applied to list on the Nasdaq under SIGQU. Read more.
